Innovative Drug Pipeline InMed Pharmaceuticals is advancing a proprietary pipeline of small molecule drug candidates targeting CB1/CB2 receptors for Alzheimer's, ocular, and dermatological conditions, presenting opportunities to connect with healthcare providers and institutions involved in these high unmet need areas.

Cannabinoid Expertise With a strong focus on rare cannabinoids and proprietary analogs through its subsidiary BayMedica, InMed is a leader in cannabinoid-based product development, indicating potential partnerships with pharma and biotech firms interested in cannabinoid therapeutics.

Strategic Expansion Recent appointments to the Board of Directors and Scientific Advisory Board, including reputed experts and industry leaders, suggest InMed's commitment to growth and innovation, presenting opportunities for collaboration with advanced research organizations.

Funding and Growth The company plans to raise nearly 7 million CAD in funding, emphasizing its ongoing development phase and creating potential sales opportunities related to research support, clinical trial services, and specialized medical supplies.

Market Positioning Active participation in major conferences like AAIC and emerging growth events highlights InMed's increasing visibility in the biotech space, pointing to opportunities for sales engagement with pharmaceutical companies, investors, and research institutions focused on neurodegenerative and cannabinoid therapies.